Comparing ITC Results From Lenvatinib Plus Everolimus For Second-Line Treatment of Advanced/Metastatic Renal Cell Carcinoma- Crossover Versus No Crossover
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.106
https://www.valueinhealthjournal.com/article/S1098-3015(17)30440-0/fulltext
Title :
Comparing ITC Results From Lenvatinib Plus Everolimus For Second-Line Treatment of Advanced/Metastatic Renal Cell Carcinoma- Crossover Versus No Crossover
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30440-0&doi=10.1016/j.jval.2017.08.106
First page :
A415
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
87